reports
Minerva Announces Leadership Transition
Minerva Announces Leadership Transition Jim O’Connor joins as Chief Business Officer and General Counsel BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O’Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company’s President, has elected to leave the company. Mr. Race will continue to be involved with Minerva as ...
Minerva Neurosciences Announces First Patient Screened in Global Phase...
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders...
Minerva Neurosciences Presents Data from its Open-label Safety Trial E...
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system di...
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Fo...
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026. The Stifel 2026 Virtual CNS ForumFormat:Company presentationDay/Time:Wednesday, March 18 at 8.30 AM ETWebcast:Webcast Link: ...
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Fina...
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided business updates and reported financial results for the fourth quarter and year ended December 31, 2025. B...
Minerva Neurosciences to Participate in The Citizens Life Sciences Con...
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL. The Citizens Life Sciences ConferenceFormat:Company presentationDay/Time: Tuesday, March 10 at 9:35 AM ...
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidon...
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026 at 10:30 AM ET featuring Gregory Strauss, PhD (Franklin Prof...
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Boar...
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company successfully raising up to $200 million in a private ...
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and...
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2025 ending September 30, 2025. Business Updates On October 23, 2025, the Company received $80 million in gross proceeds in a , before deducting fees and other expenses. The financing includes an initial upfront funding of ...
Minerva Neurosciences Announces Financing of up to $200 Million to Adv...
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission.Further $40 million proceeds may be received in connection with cas...
Minerva Neurosciences Provides Business Updates and Second Quarter Fin...
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today provided business updates. FDA Discussions & Roluperidone Update The Company has had multiple interactions with the FDA following (CRL) f...
Minerva Neurosciences Reports First Quarter 2025 Financial Results and...
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter of 2025 ended on March 31, 2025. Corporate Update On March 17, 2025, we were formally notified by Nasdaq that we had regained compliance with Nasdaq Listing Rule 5550(b)(3), and as such, will continue to be listed on the Nasdaq...
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Fina...
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2024. Corporate Update As previously in the first quarter of 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA...
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and...
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024. Roluperidone NDA Update As in February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone (f/k/a M...
Minerva Neurosciences Reports Second Quarter 2024 Financial Results an...
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates BURLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the second quarter of 2024 ending June 30, 2024. Roluperidone NDA Update During the first quarter of this year, the Company that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its New Drug Applicatio...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024. Roluperidone NDA Update On February 27, 2024, the Company that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its New Drug Applic...
Minerva Neurosciences Receives Complete Response Letter from FDA for N...
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients w...
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Fina...
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023. Corporate Update On May 8 2023, the U.S. Food and Drug Administration (FDA) confirmed acceptance for filing of Minerva’s New Drug Application (NDA) for roluperidone for the treat...
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and...
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter ended September 30, 2023. The Company continues to work with the U.S. Food and Drug Administration (FDA) during its review of its New Drug Application (NDA) for roluperidone for the treatment of negative symptoms of schizophrenia, ...
Minerva Neurosciences Reports 2023 Second Quarter Financial Results an...
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second quarter ended June 30, 2023. “In the second quarter, we completed an equity financing of $20.0 million, further strengthening our cash position. This investment from Boehringer Ingelheim and Federated Hermes Kaufman Funds comes as we...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.